Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 03; 233:141-148.

View in: PubMed

subject areas

Adrenergic beta-Antagonists
Age Factors
Aged
Canagliflozin
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Diuretics
Double-Blind Method
Female
Heart Failure
Humans
Male
Middle Aged
Placebos
Renal Insufficiency, Chronic
Sex Factors

authors with profiles

George Bakris